339 related articles for article (PubMed ID: 34097994)
21. What is killing people with hepatitis C virus infection? Analysis of a population-based cohort in Canada.
Krajden M; Cook DA; Wong S; Yu A; Butt ZA; Rossi C; Darvishian M; Alvarez M; Buxton JA; Tyndall M; Janjua NZ
Int J Drug Policy; 2019 Oct; 72():114-122. PubMed ID: 31229445
[TBL] [Abstract][Full Text] [Related]
22. Impact of Hepatitis C Virus Infection and Treatment on Mortality in the Country of Georgia, 2015-2020.
Gvinjilia L; Baliashvili D; Shadaker S; Averhoff F; Kandelaki L; Kereselidze M; Tsertsvadze T; Chkhartishvili N; Butsashvili M; Metreveli D; Gamkrelidze A; Armstrong PA
Clin Infect Dis; 2023 Aug; 77(3):405-413. PubMed ID: 37099136
[TBL] [Abstract][Full Text] [Related]
23. Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study.
Butt AA; Yan P; Shaikh OS; Lo Re V; Abou-Samra AB; Sherman KE
J Hepatol; 2020 Aug; 73(2):277-284. PubMed ID: 32145260
[TBL] [Abstract][Full Text] [Related]
24. Impact of Hepatitis B Virus Infection, Non-alcoholic Fatty Liver Disease, and Hepatitis C Virus Co-infection on Liver-Related Death among People Tested for Hepatitis B Virus in British Columbia: Results from a Large Longitudinal Population-Based Cohort Study.
Makuza JD; Jeong D; Binka M; Adu PA; Cua G; Yu A; Velásquez García HA; Alvarez M; Wong S; Bartlett S; Karim ME; Yoshida EM; Ramji A; Krajden M; Janjua NZ
Viruses; 2022 Nov; 14(11):. PubMed ID: 36423186
[TBL] [Abstract][Full Text] [Related]
25. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
26. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
27. Impact of Direct-acting Antivirals on Hepatocellular Carcinoma and Mortality Among Medicaid Beneficiaries With Hepatitis C.
Jiang X; Song HJ; Chang CY; Wilson DL; Lo-Ciganic WH; Park H
Med Care; 2023 Aug; 61(8):505-513. PubMed ID: 37223993
[TBL] [Abstract][Full Text] [Related]
28. Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada.
Selfridge M; Cunningham EB; Milne R; Drost A; Barnett T; Lundgren K; Guarasci K; Grebely J; Fraser C
Int J Drug Policy; 2019 Oct; 72():106-113. PubMed ID: 31178254
[TBL] [Abstract][Full Text] [Related]
29. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals.
Corma-Gómez A; Morano L; Téllez F; Rivero-Juárez A; Real LM; Alados JC; Ríos-Villegas MJ; Vera-Méndez FJ; Muñoz RP; Geijo P; Macías J; Pineda JA;
AIDS; 2019 Jun; 33(7):1167-1174. PubMed ID: 30845068
[TBL] [Abstract][Full Text] [Related]
30. Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.
Isfordink CJ; Boyd A; Sacks-Davis R; van Santen DK; Smit C; Martinello M; Stoove M; Berenguer J; Wittkop L; Klein MB; Rauch A; Salmon D; Lacombe K; Stewart A; Schinkel J; Doyle JS; Hellard M; van der Valk M; Matthews GV;
Lancet Public Health; 2023 Apr; 8(4):e294-e304. PubMed ID: 36965984
[TBL] [Abstract][Full Text] [Related]
31. Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.
Janjua NZ; Islam N; Wong J; Yoshida EM; Ramji A; Samji H; Butt ZA; Chong M; Cook D; Alvarez M; Darvishian M; Tyndall M; Krajden M
J Viral Hepat; 2017 Aug; 24(8):624-630. PubMed ID: 28130810
[TBL] [Abstract][Full Text] [Related]
32. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.
Nahon P; Bourcier V; Layese R; Audureau E; Cagnot C; Marcellin P; Guyader D; Fontaine H; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Leroy V; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Dharancy S; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Benhamou Y; Pilette C; Silvain C; Christidis C; Capron D; Bernard-Chabert B; Zucman D; Di Martino V; Thibaut V; Salmon D; Ziol M; Sutton A; Pol S; Roudot-Thoraval F;
Gastroenterology; 2017 Jan; 152(1):142-156.e2. PubMed ID: 27641509
[TBL] [Abstract][Full Text] [Related]
33. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E;
Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138
[TBL] [Abstract][Full Text] [Related]
34. Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort.
Calvaruso V; Petta S; Cacciola I; Cabibbo G; Cartabellotta F; Distefano M; Scifo G; Di Rosolini MA; Russello M; Prestileo T; Madonia S; Malizia G; Montineri A; Digiacomo A; Licata A; Benanti F; Bertino G; Enea M; Battaglia S; Squadrito G; Raimondo G; Cammà C; Craxì A; Di Marco V;
J Viral Hepat; 2021 Aug; 28(8):1190-1199. PubMed ID: 33896097
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis C virus infection and risk of liver-related and non-liver-related deaths: a population-based cohort study in Naples, southern Italy.
Piselli P; Serraino D; Fusco M; Girardi E; Pirozzi A; Toffolutti F; Cimaglia C; Taborelli M;
BMC Infect Dis; 2021 Jul; 21(1):667. PubMed ID: 34238231
[TBL] [Abstract][Full Text] [Related]
36. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB
Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197
[TBL] [Abstract][Full Text] [Related]
37. High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study.
Yee J; Carson JM; Hajarizadeh B; Hanson J; O'Beirne J; Iser D; Read P; Balcomb A; Doyle JS; Davies J; Martinello M; Marks P; Dore GJ; Matthews GV;
Hepatol Commun; 2022 Mar; 6(3):496-512. PubMed ID: 34729957
[TBL] [Abstract][Full Text] [Related]
38. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
39. The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection.
El-Serag HB; Christie IC; Puenpatom A; Castillo D; Kanwal F; Kramer JR
Aliment Pharmacol Ther; 2019 Jun; 49(11):1442-1447. PubMed ID: 30932218
[TBL] [Abstract][Full Text] [Related]
40. Factors associated with lost to follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program, Vancouver, Canada.
Nouch S; Gallagher L; Erickson M; Elbaharia R; Zhang W; Wang L; Bacani N; Kason D; Kleban H; Knebel L; Hall D; Barrios R; Hull M
Int J Drug Policy; 2018 Sep; 59():76-84. PubMed ID: 30048877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
